PL2225233T3 - Pochodna oksadiazolu aktywna wobec sfingozyno-1-fosforanu (S1P) - Google Patents

Pochodna oksadiazolu aktywna wobec sfingozyno-1-fosforanu (S1P)

Info

Publication number
PL2225233T3
PL2225233T3 PL08863529T PL08863529T PL2225233T3 PL 2225233 T3 PL2225233 T3 PL 2225233T3 PL 08863529 T PL08863529 T PL 08863529T PL 08863529 T PL08863529 T PL 08863529T PL 2225233 T3 PL2225233 T3 PL 2225233T3
Authority
PL
Poland
Prior art keywords
sphingosine
phosphate
oxadiazole derivative
derivative active
active
Prior art date
Application number
PL08863529T
Other languages
English (en)
Inventor
Jag Paul Heer
Thomas Daniel Heightman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL2225233T3 publication Critical patent/PL2225233T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08863529T 2007-12-21 2008-12-19 Pochodna oksadiazolu aktywna wobec sfingozyno-1-fosforanu (S1P) PL2225233T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0725101.0A GB0725101D0 (en) 2007-12-21 2007-12-21 Compounds
EP08863529.7A EP2225233B1 (en) 2007-12-21 2008-12-19 Oxadiazole derivative active on sphingosine-1-phosphate (s1p)
PCT/EP2008/067963 WO2009080724A1 (en) 2007-12-21 2008-12-19 Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)

Publications (1)

Publication Number Publication Date
PL2225233T3 true PL2225233T3 (pl) 2014-01-31

Family

ID=39048651

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08863529T PL2225233T3 (pl) 2007-12-21 2008-12-19 Pochodna oksadiazolu aktywna wobec sfingozyno-1-fosforanu (S1P)

Country Status (23)

Country Link
US (2) US8278324B2 (pl)
EP (2) EP2225233B1 (pl)
JP (1) JP2011506568A (pl)
KR (1) KR20100108568A (pl)
CN (1) CN101945864A (pl)
AU (1) AU2008339987B2 (pl)
BR (1) BRPI0821069A2 (pl)
CA (1) CA2710067A1 (pl)
CO (1) CO6290688A2 (pl)
CR (1) CR11578A (pl)
DK (1) DK2225233T3 (pl)
DO (1) DOP2010000187A (pl)
EA (1) EA018637B1 (pl)
ES (1) ES2431795T3 (pl)
GB (1) GB0725101D0 (pl)
HR (1) HRP20131053T1 (pl)
IL (1) IL206278A0 (pl)
MA (1) MA31922B1 (pl)
NZ (1) NZ585994A (pl)
PL (1) PL2225233T3 (pl)
PT (1) PT2225233E (pl)
UA (1) UA102539C2 (pl)
WO (1) WO2009080724A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725101D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
EP2481740B1 (en) * 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
HUE039931T2 (hu) 2013-02-20 2019-02-28 Lg Chemical Ltd Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények
CN110831593A (zh) * 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
EP1549640A4 (en) * 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CN102174042B (zh) 2003-05-19 2013-09-18 Irm有限责任公司 免疫抑制剂化合物和组合物
EP1628967B1 (en) * 2003-05-19 2014-04-09 Irm Llc Immunosuppressant compounds and compositions
AU2004240649A1 (en) * 2003-05-19 2004-12-02 Irm, Llc Immunosuppressant compounds and compositions
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. S1p受容体結合能を有する化合物およびその用途
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
CA2591399C (en) * 2004-12-13 2014-05-20 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
WO2006100633A1 (en) * 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS
WO2006115188A1 (ja) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited ヘテロ環化合物
US20080306124A1 (en) * 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
CN101291908A (zh) * 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
EP2003132B1 (en) * 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
JP2010510251A (ja) * 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン=1−燐酸受容体活性を有するベンゾシクロヘプチルアナログ
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725101D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CO6290688A2 (es) 2011-06-20
EP2746254A3 (en) 2014-10-15
KR20100108568A (ko) 2010-10-07
MA31922B1 (fr) 2010-12-01
EP2225233B1 (en) 2013-09-04
JP2011506568A (ja) 2011-03-03
AU2008339987A1 (en) 2009-07-02
CA2710067A1 (en) 2009-07-02
GB0725101D0 (en) 2008-01-30
HRP20131053T1 (hr) 2013-12-06
DK2225233T3 (da) 2013-10-14
EA201070781A1 (ru) 2010-12-30
WO2009080724A1 (en) 2009-07-02
EP2746254A2 (en) 2014-06-25
NZ585994A (en) 2012-02-24
PT2225233E (pt) 2013-11-22
CN101945864A (zh) 2011-01-12
ES2431795T3 (es) 2013-11-28
CR11578A (es) 2010-09-23
EA018637B1 (ru) 2013-09-30
US20100273827A1 (en) 2010-10-28
DOP2010000187A (es) 2010-08-15
US8278324B2 (en) 2012-10-02
US20100152235A1 (en) 2010-06-17
EP2225233A1 (en) 2010-09-08
BRPI0821069A2 (pt) 2015-06-16
AU2008339987B2 (en) 2013-03-21
UA102539C2 (ru) 2013-07-25
IL206278A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
IL206235A0 (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
IL206278A0 (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
EP2141990A4 (en) ACTIVE COMPOUNDS ON 11BETA-HSD1
JP1322466S (en) An earphone
ZA201104423B (en) Oxadiazole derivatives
KR101608166B9 (ko) 펌프 카세트
PL2520575T3 (pl) Związek 1,3,4-oksadiazolo-2-karboksyamidowy
PL2003132T3 (pl) Pochodne oksadiazolu jako agoniści S1P1
IL200870A0 (en) Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
IL196101A0 (en) C-phenyl 1-thioglucitol compound
EP2156296A4 (en) STORAGE IN CLUSTERS USING UNDER-SEGMENTATION
IL207757A0 (en) Hererocyclic compound
EP2355898A4 (en) HOUSING STRUCTURE FOR A MEDICAL IMPLANT COMPRISING A MONOLITHIC SUBSTRATE
GB0716026D0 (en) An inhalable medicament
WO2009085272A3 (en) Improved medical devices
PL2154968T3 (pl) Kombinacje grzybobójczych substancji czynnych
IL199771A0 (en) Active substance combination
IL224071B (en) 5-(biphenyl-r-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors
GB0722340D0 (en) Sphingosine-1-phosphate (S1P) receptor compounds
IL197008A0 (en) Improved storage performance
HK1142071A (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
TWI346662B (en) Oxadiazole compounds
GB0708415D0 (en) Insert for high stress connection
ZA200906256B (en) Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
HK1133371A (en) 11beta-hsd1 active compounds